Eosinophilic gastroenteritis (EGE) is a rare benign gastrointestinal disease characterized by the presence of abnormal and nonspecific gastro-intestinal (GI) manifestations, associated with an eosinop...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
The documentation surrounding eosinophilic gastroenteritis is limited primarily due to its rarity, affecting fewer than 10,000 individuals in the U.S. This low prevalence results in fewer systematic studies and clinical characterizations. Additionally, the clinical features can be nonspecific and overlap with other gastrointestinal disorders, making it challenging to establish a comprehensive understanding of the condition.
To navigate eosinophilic gastroenteritis, consider consulting a gastroenterologist who specializes in eosinophilic disorders. They can provide tailored management strategies and support. You may also benefit from connecting with the American Partnership for Eosinophilic Disorders (APFED) at https://apfed.org, which offers resources and support for patients and families. Additionally, inquire about opportunities to participate in clinical trials or registries that focus on eosinophilic gastroenteritis, as these can provide valuable insights into the condition.
Currently, there are 69 active clinical trials investigating various aspects of eosinophilic gastroenteritis. These trials may focus on treatment options, symptom management, or understanding the disease better. For more information on specific trials and participation eligibility, you can visit ClinicalTrials.gov and search for eosinophilic gastroenteritis: https://clinicaltrials.gov/search?cond=eosinophilic%20gastroenteritis.
Actionable guidance for navigating care for eosinophilic gastroenteritis
To navigate eosinophilic gastroenteritis, consider consulting a gastroenterologist who specializes in eosinophilic disorders. They can provide tailored management strategies and support. You may also benefit from connecting with the American Partnership for Eosinophilic Disorders (APFED) at https://apfed.org, which offers resources and support for patients and families. Additionally, inquire about opportunities to participate in clinical trials or registries that focus on eosinophilic gastroenteritis, as these can provide valuable insights into the condition.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the eosinophilic gastroenteritis community
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
1 peer-reviewed source from PubMed
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning eosinophilic gastroenteritis
Updated Mar 12, 2012
A CDC study reveals that deaths from gastroenteritis more than doubled between 1999 and 2007, highlighting a significant public health concern. This inflammation of the stomach and intestines leads to severe vomiting and diarrhea.